Anemia

In adult patients with primary autoimmune hemolytic anemia (AIHA) undergoing rituximab treatment, there was a notable prevalence of hospitalizations due to infections, with a subsequent high mortality rate post-hospitalization, according to the results of a prospective study. The development of auto-antibodies against the red blood cells underlies the pathology of autoimmune hemolytic anemia (AIHA), which...

Sutimlimab is generally well tolerated, and the frequency and nature of treatment-emergent adverse events are consistent with those observed in elderly, medically complex patients, according to an analysis of data from two phase 3 studies. Cold agglutinin disease (CAD) is characterized by autoimmune hemolytic anemia mediated by the classical complement pathway. Sutimlimab, a monoclonal humanized...

The administration of zinc supplements proved to be effective in treating anemia, resulting in full recovery in 35% and a progressive increase in hemoglobin concentrations over the course of one year in chronic kidney disease patients with zinc deficiency and anemia, as reported in a retrospective study. Anemia in chronic kidney disease (CKD) is associated...

This study will investigate the use of bitopertin, an oral GlyT1 glycine transporter inhibitor, in treating steroid-refractory Diamond–Blackfan anemia, which is characterized by bone marrow failure and often exhibits poor response to systemic corticosteroids. Bitopertin aims to rebalance hemoglobin synthesis by slowing heme production.  Diamond–Blackfan anemia (DBA) is described as a bone marrow failure disorder....

On Monday November 25 the U.S. Food and Drug Administration granted accelerated approval to Oxbryta (voxelotor) for the treatment of sickle cell disease (SCD) in adults and pediatric patients 12 years of age and older. “Today’s approval provides additional hope to the 100,000 people in the U.S., and the more than 20 million globally, who...

On November 15 the U.S. Food and Drug Administration approved Adakveo (crizanlizumab-tmca), a treatment to reduce the frequency of vaso-occlusive crisis – a common and painful complication of sickle cell disease that occurs when blood circulation is obstructed by sickled red blood cells – for patients age 16 years and older. “Hope has never been...